Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial

Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone

(2018) Netanya S Utay et al.   JOURNAL OF INFECTIOUS DISEASES

Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients

(2017) María J. Villanueva-Millán et al.   Journal of the International AIDS Society

The Role of Transforming Growth Factor Beta-1 in the Progression of HIV/AIDS and Development of Non-AIDS-Defining Fibrotic Disorders

(2017) Annette J. Theron et al.   Frontiers in Immunology

Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients

(2016) Sergio Serrano-Villar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s

(2016) Theodoros Kelesidis et al.   JOURNAL OF INFECTIOUS DISEASES

Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era

(2016) Wei Cao et al.   Journal of the International AIDS Society

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

(2016) Sergio Serrano-Villar et al.   PLoS Pathogens

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s

(2015) Theodoros Kelesidis et al.   CLINICAL INFECTIOUS DISEASES

Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study

(2015) Jordan E. Lake et al.   HIV CLINICAL TRIALS

Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study

(2015) F. De Salvador-Guillouët et al.   PLoS One

HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality

(2014) Sergio Serrano-Villar et al.   PLoS Pathogens

Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation

(2013) Michael J. Vinikoor et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial

(2013) Jordan E. Lake et al.   PLoS One

A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection

(2012) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study

(2011) Josep M Llibre et al.   ANTIVIRAL THERAPY

Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients

(2010) Alba Diaz et al.   AIDS

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Serum Immune Activation Markers Are Persistently Increased in Patients with HIV Infection after 6 Years of Antiretroviral Therapy despite Suppression of Viral Replication and Reconstitution of CD4+T Cells

(2009) Martyn A. French et al.   JOURNAL OF INFECTIOUS DISEASES

Regulation of T-cell function by endogenously produced angiotensin II

(2008) Nyssa E. Hoch et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY